Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancerCancer Diagnostic

PUBLISHER: TechSci Research | PRODUCT CODE: 1953421

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1953421

Uterine Cancer Therapeutics & Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type, By Therapeutics, By Diagnostics, By Region & Competition, 2021-2031F

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2-3 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4500
PDF and Excel (Multi-User License)
USD 5500
PDF and Excel (Custom Research License)
USD 8000

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

Description

Table of Contents

The Global Uterine Cancer Therapeutics & Diagnostics Market is projected to expand from USD 23.21 Billion in 2025 to USD 32.57 Billion by 2031, registering a CAGR of 5.81%. This market includes pharmaceutical agents, surgical interventions, and diagnostic technologies aimed at managing endometrial cancer and uterine sarcoma. Growth is largely fueled by the increasing prevalence of risk factors such as obesity and hormonal imbalances in postmenopausal women, alongside government efforts to improve healthcare infrastructure and promote early screening programs.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 23.21 Billion
Market Size 2031USD 32.57 Billion
CAGR 2026-20315.81%
Fastest Growing SegmentEndometrial Adenocarcinoma
Largest MarketNorth America

Despite these positive drivers, the high cost of advanced immunotherapies and targeted drug delivery systems poses a major barrier to accessibility, particularly in developing regions. This economic challenge persists even as the disease burden grows; the American Cancer Society estimated that 67,880 new cases of uterine corpus cancer would be diagnosed in the United States in 2024. Consequently, financial constraints related to long-term care remain a significant impediment to the broader expansion of the market.

Market Driver

A primary engine for market growth is the accelerated regulatory approval of novel targeted therapies and immunotherapies, which are reshaping the standard of care for advanced endometrial carcinoma. Regulatory bodies are increasingly clearing immune checkpoint inhibitors, such as the FDA's June 2024 approval of durvalumab with chemotherapy for mismatch repair deficient tumors, a decision supported by the DUO-E clinical trial of 718 patients. These authorizations allow pharmaceutical developers to commercialize biologics that replace traditional chemotherapy in recurrent disease settings, incentivizing further investment in the oncology pipeline.

Additionally, the rising global incidence of uterine malignancies, driven by aging populations and lifestyle factors, necessitates an expansion of diagnostic and therapeutic availability. This growing burden is evident internationally, with the Canadian Cancer Society's May 2024 report projecting 8,700 new uterine cancer diagnoses in Canada for the year. This increasing prevalence translates into substantial commercial returns, as demonstrated by GSK's report that sales of the endometrial cancer treatment Jemperli reached £102 million in the third quarter of 2024 alone.

Market Challenge

The significant expense associated with advanced immunotherapies and targeted drug delivery systems acts as a major restraint on the uterine cancer market's growth. In areas with insufficient healthcare funding or limited insurance coverage, the high price of these agents restricts patient access and adoption, compelling healthcare providers to utilize older, less expensive alternatives. This economic barrier limits the widespread implementation of newer treatment protocols and subsequently reduces the revenue potential for manufacturers of advanced therapeutics.

These financial constraints are particularly impactful given the severe outcomes of the disease, which require effective intervention. The American Cancer Society projected approximately 13,250 deaths from uterine corpus cancer in the United States in 2024, highlighting the urgent clinical need. However, the prohibitive costs linked to long-term management and novel drug regimens continue to hinder market penetration, maintaining a gap between clinical requirements and economic feasibility that slows the sector's overall commercial expansion.

Market Trends

The rise of antibody-drug conjugates (ADCs) targeting HER2-positive disease represents a significant evolution in the management of uterine malignancies, especially serous carcinomas. Validating this trend, the FDA granted accelerated approval in April 2024 to fam-trastuzumab deruxtecan-nxki based on the DESTINY-PanTumor02 trial, which demonstrated an objective response rate of 51.4%. This approach delivers cytotoxic payloads directly to cancer cells via antibodies, minimizing systemic toxicity compared to traditional methods and offering a new precision medicine avenue for patients who have exhausted standard treatments.

Simultaneously, the adoption of robot-assisted minimally invasive surgical techniques is redefining the standard for hysterectomy and staging procedures. These platforms offer surgeons greater dexterity and visualization, which is particularly beneficial for the obese patient demographic often associated with this condition, while also reducing post-operative complications. The expanding reliance on this technology is underscored by Intuitive Surgical's October 2024 report, which noted an approximate 18% year-over-year growth in worldwide da Vinci procedures, supporting healthcare providers in managing increasing patient volumes.

Key Market Players

  • Ariad Pharmaceuticals, Inc.
  • Abbott Laboratories Inc.
  • Becton, Dickinson & Co.
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi SA
  • Siemens Healthineers AG.
  • F. Hoffmann-La Roche AG

Report Scope

In this report, the Global Uterine Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uterine Cancer Therapeutics & Diagnostics Market, By Cancer Type

  • Endometrial Adenocarcinoma
  • Adenosquamous Carcinoma
  • Papillary Serous Carcinoma
  • Uterine Sarcoma

Uterine Cancer Therapeutics & Diagnostics Market, By Therapeutics

  • Surgery
  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • others

Uterine Cancer Therapeutics & Diagnostics Market, By Diagnostics

  • Biopsy
  • Pelvic Ultrasound
  • Hysteroscopy
  • Dilation and Curettage
  • CT scan

Uterine Cancer Therapeutics & Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uterine Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Uterine Cancer Therapeutics & Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Show more
Product Code: 17599

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cancer Type (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma)
    • 5.2.2. By Therapeutics (Surgery, Immunotherapy, Radiation Therapy, Chemotherapy, others)
    • 5.2.3. By Diagnostics (Biopsy, Pelvic Ultrasound, Hysteroscopy, Dilation and Curettage, CT scan)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Type
    • 6.2.2. By Therapeutics
    • 6.2.3. By Diagnostics
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cancer Type
        • 6.3.1.2.2. By Therapeutics
        • 6.3.1.2.3. By Diagnostics
    • 6.3.2. Canada Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cancer Type
        • 6.3.2.2.2. By Therapeutics
        • 6.3.2.2.3. By Diagnostics
    • 6.3.3. Mexico Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cancer Type
        • 6.3.3.2.2. By Therapeutics
        • 6.3.3.2.3. By Diagnostics

7. Europe Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Type
    • 7.2.2. By Therapeutics
    • 7.2.3. By Diagnostics
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Type
        • 7.3.1.2.2. By Therapeutics
        • 7.3.1.2.3. By Diagnostics
    • 7.3.2. France Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Type
        • 7.3.2.2.2. By Therapeutics
        • 7.3.2.2.3. By Diagnostics
    • 7.3.3. United Kingdom Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Type
        • 7.3.3.2.2. By Therapeutics
        • 7.3.3.2.3. By Diagnostics
    • 7.3.4. Italy Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Type
        • 7.3.4.2.2. By Therapeutics
        • 7.3.4.2.3. By Diagnostics
    • 7.3.5. Spain Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Type
        • 7.3.5.2.2. By Therapeutics
        • 7.3.5.2.3. By Diagnostics

8. Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Type
    • 8.2.2. By Therapeutics
    • 8.2.3. By Diagnostics
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Type
        • 8.3.1.2.2. By Therapeutics
        • 8.3.1.2.3. By Diagnostics
    • 8.3.2. India Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Type
        • 8.3.2.2.2. By Therapeutics
        • 8.3.2.2.3. By Diagnostics
    • 8.3.3. Japan Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Type
        • 8.3.3.2.2. By Therapeutics
        • 8.3.3.2.3. By Diagnostics
    • 8.3.4. South Korea Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Type
        • 8.3.4.2.2. By Therapeutics
        • 8.3.4.2.3. By Diagnostics
    • 8.3.5. Australia Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Type
        • 8.3.5.2.2. By Therapeutics
        • 8.3.5.2.3. By Diagnostics

9. Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Type
    • 9.2.2. By Therapeutics
    • 9.2.3. By Diagnostics
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Type
        • 9.3.1.2.2. By Therapeutics
        • 9.3.1.2.3. By Diagnostics
    • 9.3.2. UAE Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Type
        • 9.3.2.2.2. By Therapeutics
        • 9.3.2.2.3. By Diagnostics
    • 9.3.3. South Africa Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Type
        • 9.3.3.2.2. By Therapeutics
        • 9.3.3.2.3. By Diagnostics

10. South America Uterine Cancer Therapeutics & Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Type
    • 10.2.2. By Therapeutics
    • 10.2.3. By Diagnostics
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Type
        • 10.3.1.2.2. By Therapeutics
        • 10.3.1.2.3. By Diagnostics
    • 10.3.2. Colombia Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Type
        • 10.3.2.2.2. By Therapeutics
        • 10.3.2.2.3. By Diagnostics
    • 10.3.3. Argentina Uterine Cancer Therapeutics & Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Type
        • 10.3.3.2.2. By Therapeutics
        • 10.3.3.2.3. By Diagnostics

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Uterine Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Ariad Pharmaceuticals, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc.
  • 15.3. Becton, Dickinson & Co.
  • 15.4. GlaxoSmithKline Plc
  • 15.5. Merck & Co., Inc.
  • 15.6. Novartis AG
  • 15.7. Sanofi SA
  • 15.8. Siemens Healthineers AG.
  • 15.9. F. Hoffmann-La Roche AG

16. Strategic Recommendations

17. About Us & Disclaimer

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!